By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Shares of Myriad Genetics fell around 5 percent in Tuesday trade following yesterday's ruling by a federal District Court that declared Myriad's BRCA gene patents invalid.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.
The new Riken president outlines some of his plans for the institute.